Literature DB >> 348314

Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.

P L Frederiksen, S T Joergensen, K Roesdahl, J Thomsen, H T Mouridsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 348314

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  3 in total

Review 1.  Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.

Authors:  J Greidanus; P H Willemse; D R Uges; E T Oremus; Z J De Langen; E G De Vries
Journal:  Pharm Weekbl Sci       Date:  1988-12-09

2.  Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer.

Authors:  A Sulkes; E Gez; M R Pfeffer; R Catane; R Isacson; S Biran
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.

Authors:  P A Vasey; H Roché; D Bisset; C Terret; L Vernillet; A Riva; C Ramazeilles; N Azli; S B Kaye; C J Twelves
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.